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Estrogens play a critical role in the normal growth and development of humans and in recent years our understanding of
their effects in the central nervous system (CNS) have been advancing rapidly. It is now known that estrogens influence
synaptic plasticity, brain development, and memory. In addition, estrogens have been shown to be neuroprotective in
degenerative disorders. The understanding of the influences of estrogens in the retina, as a component of the CNS, has
not kept pace with the advances in understanding of the brain. Studies that have addressed the effects of estrogens on the
retina, specifically those focusing on glaucoma, are examined here in the hope that estrogen therapy may be a viable option
for treating retinal dystrophies and optic neuropathies.
Glaucomatous  visual  field  deterioration  is  a
neurodegenerative  process  commonly  associated  with  an
insidious  increase  in  intraocular  pressure  (IOP),  with
characteristic optic disc and retinal ganglion cell (RGC) nerve
fiber layer damage [1,2]. World Health Organization statistics
indicate that glaucoma accounts for blindness in at least 5
million people, causing 13.5% of worldwide blindness [3]. In
the United States, glaucoma is the second leading cause of
blindness and the second most frequent reason for ambulatory
visits  to  physicians  by  U.S.  Medicare  beneficiaries  [4].
Extrapolating to the entire Medicare population, blindness and
vision loss are associated with greater than $2 billion in non-
ophthalmologic related costs. The staggering healthcare and
economic burdens make vision loss a medical imperative [5].
In recent years, there has been compelling evidence to
support  the  use  of  estrogens  as  neuroprotectants  [6-13].
However, the Women’s Health Initiative Study concluded that
conjugated  equine  estrogens  and  estrogen  plus
medroxyprogesterone acetate increase the risk for ischemic
stroke in generally healthy postmenopausal women [14,15].
Additional findings indicate that low doses of 17β-estradiol
may protect against ischemia and reperfusion injury [16,17].
A correlation between glaucoma and ophthalmic artery blood
flow  changes  with  hormone  therapy  (HT),  female
reproductive factors, as well as HT and IOP clearly illustrate
that  estrogens  influence  the  health  of  the  retina  [18-22].
Nonetheless,  the  use  of  estrogens  as  neuroprotectants  is
complicated by the natural feminizing sequelae that would be
undesired in male patients, and therefore it becomes important
to  investigate  use  of  synthetic  non-feminizing  estrogen
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analogs. With an emphasis on glaucoma as the primary retinal
neurodegenerative  disease,  this  review  examines  whether
estrogens can be effective neuroprotectants in the retina.
Estrogen  receptor  expression  in  the  retina:  Estrogen
receptors α and β (ERα and ERβ) are involved in classic
receptor-mediated genomic pathways as well as alternative
mechanisms  of  orchestrating  neuroprotection  [12,13,23].
Bovine  and  rat  retinas  have  been  shown  to  express  both
receptor isoforms (ERα predominates in rat) throughout the
retinal thickness, seen in greatest density within the ganglion
cell layer, the inner nuclear layer, and the outer portion of the
outer  nuclear  layer  [24,25].  Human  donor  eyes  from
premenopausal women have been found to express ERα in the
neurosensory  retina  and  retinal  pigment  epithelium,  but
receptors have not been detected in tissues dissected from men
and  postmenopausal  women  [26].  Another  study  of  ER
expression in humans showed that ERβ protein was localized
to  the  ganglion  cell  layer  and  choroid.  However,  at  the
transcriptional level both ERα and ERβ were observed with
local differences in expression, suggesting variability in the
ratio of ERα:ERβ [27]. ERs have also been detected in the
neuroendocrine secretory and metabolic ciliary epithelium.
17β-hydroxysteroid dehydrogenases (17HSDs), involved in
the biosynthesis and inactivation for sex steroids, were shown
to  be  under  direct  paracrine  influence  of  17β-estradiol,
evidence of estrogen modulating its own fate within the eye
[28].  The  presence  of  estrogen  receptors  and  metabolic
machinery within the eye suggest that estrogens play more
than a passive role in the retina.
Retinal estrogenic effects: Given the intimate association
between estrogens, their receptors, and their metabolism in
the eye, is it possible that estrogens could have deleterious
effects similar to those seen with HT in the Women’s Health
Initiative Study? Rather than producing hypercoagulability, it
appears that HT in older women does not have a long-term
vasodilatory effect on retinal arterioles. These studies were
based on the coronary vessel and incidence of myocardial
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1480infarction studies in fertile women, and does not support the
hypothesis that exogenous estrogen exposure accounts for
greater observed retinal arteriolar diameters in women [29].
Curiously, blood viscosity is decreased and ocular vascularity
is improved in women with glaucoma who receive HT [19].
Neither of these studies clearly indicate what role, if any, HT
plays in glaucoma. Is it possible then that gender differences
or exposure to endogenous feminizing hormones could affect
IOP and the development of glaucoma? This question was the
basis for investigations that examined the effect of HT on IOP
in a single case study and three large international studies
examining  female  reproductive  factors  as  risks  for  the
development of open angle glaucoma (OAG). An early case
study examined IOP changes with initiation of HT through 12
weeks of treatment. After the initiation of HT treatment of one
glaucoma  patient  who  had  menopausal  symptoms,  it  was
found IOP was reduced by an average of 4.5 mmHg at four
weeks and by an average of 4 mmHg at 12 weeks [20]. In a
larger cross-sectional controlled study, 107 women receiving
HT  and  107  women  serving  as  controls  underwent  IOP
assessment and cup-to-disc ratio assessment. In addition, they
completed  comprehensive  medical  and  family  history
questionnaires. The two groups were found to not differ in
mean IOP, cup-to-disc ratios, prevalence of elevated IOP, or
prevalence of glaucoma. A personal history of ischemic heart
disease was the only clear risk factor for increased IOP [30].
The Rotterdam Study published findings on the association
between early menopause and the development of OAG. This
population-based study concluded that early menopause (≤45
years of age), age-adjusted and controlled for HT use, was a
significant risk factor for the development of OAG [18]. The
Blue Mountain Eye Study, which examined the association
between  endogenous  estrogen  exposure  and  OAG,
determined  that  early  menarche  (age  ≤  12  years)  and
increasing parity significantly increased the risk for OAG
[22]. A similar study conducted in rural southern India found
no connection between female reproductive factors and OAG
[21]. This disparate finding may be explained by significantly
greater phytoestrogen content in the predominantly vegetarian
south Indian diet, possibly masking what may otherwise have
been an association between female reproductive factors and
OAG. This theory was supported by a study that examined
retinal  thickness  in  male  and  female  rats  whose  diet  was
supplemented  with  soy  phytoestrogens.  Male  rats  fed  a
phytoestrogen-fortified  diet  showed  an  increase  in  retinal
thickness,  while  female  rats  showed  a  decrease  in  retinal
thickness compared to control diet-fed animals [33]. These
studies equivocally suggest that HT and length of endogenous
estrogen exposure may influence the development of OAG.
Although  not  directly  relevant  to  retina,  the  risk  of
cardiovascular  disease  (CVD)  in  postmenopausal  women
receiving estrogen and progesterone has been proposed to be
due to increased levels of pro-inflammatory cytokine TNF-α
[31]. However, estrogen can also lower markers of vascular
inflammation  (IL-6  secretion),  and  thus  render  protective
effects of lower doses of 17β-estradiol in combination with
trivalent chromium therapy in diabetic monocytes [32].
Estrogens  as  neuroprotectants:  Estrogen  receptor
independent and dependent neuroprotective mechanisms have
been well established in the brain [7,12,13,34,35], but similar
studies  in  the  retina  either  are  limited  or  have  not  been
conducted. Those studies that demonstrate neuroprotective
efficacy in models of retinal disease are examined here.
One  of  the  pioneering  studies  in  estrogen-mediated
retinal neuroprotection examined the efficacy of a synthetic
estrogen analog in an in vivo model of retinitis pigmentosa
(RP)  and  in  an  in  vitro  model  of  N-methyl-D-aspartate
(NMDA)-induced excitotoxic glaucomatous RGC death. In
the RP model, treatment with an estrogen analog at postnatal
day  9  yielded  an  outer  nuclear  layer,  containing  the
photoreceptors cells lost in RP, that was nearly twice the
thickness in untreated controls [36]. In the glaucoma model,
primary RGCs treated with the same estrogen analog were
protected  from  NMDA-induced  excitotoxic  death  [36].
Furthermore, the in vitro study demonstrated maintenance of
mitochondrial stability and inhibition of lipid peroxidation.
These findings were in accord with previous reports from
brain  parenchymal  studies,  offering  a  novel  approach  to
neuroprotection in degenerative diseases of the retina [36].
Another study examined protection of cultured retinal
pigment epithelial cells (RPE), the pathologic target in age-
related macular degeneration (AMD) vision loss, by 17β-
estradiol against hydrogen peroxide-induced cell death. This
study not only demonstrated significant protection of RPE
cells, but also showed that 17β-estradiol quenched hydrogen
peroxide-induced upregulation of apoptosis-related proteins
[37].  The  large  cross-sectional  Salisbury  Eye  Evaluation
Project supported these in vitro findings. This study evaluated
the effects of HT and female reproductive factors on AMD,
showing that current HT was associated with lower odds of
large drusen predictive of advanced AMD [38]. Together,
these studies suggest that estrogen treatment may be effective
in AMD, in addition to RP and glaucoma as described in the
previous section.
Oxidative  stress,  induced  by  ischemia-reperfusion  or
other perturbations, is a ubiquitous pathway of degenerative
vision  loss.  The  effects  of  17β-estradiol  on  leukocyte
accumulation  have  been  evaluated  during  ischemia–
reperfusion injury and retinal damage after transient retinal
ischemia. Treatment with 17β-estradiol significantly inhibited
leukocyte accumulation and subsequently improved retinal
function  as  assessed  by  electroretinogram  [39].  Another
ischemic retinal study showed that 17β-estradiol protected
RGCs from early changes in synaptic connections that are
associated with ischemia preceding apoptosis and ischemia-
induced global apoptosis [40].
These studies created the foundation for the field and led
to  the  examination  of  estrogen-mediated  neuroprotective
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transcriptional  modulation  via  receptor  mediated  genomic
pathways,  but  they  may  also  alter  intracellular  signaling
cascades  [35].  One  study  approached  this  subject  by
examining estrogen-mediated retinal neuroprotection in an in
vitro  hydrogen  peroxide-induced  model  of  retinal
neurodegeneration  along  with  an  in  vivo  model  of  light-
induced photoreceptor degeneration. Both 17β-estradiol and
17α-estradiol protected retinal neurons in vitro, with 17β-
estradiol  activating  the  phosphoinositide  3-kinase  (PI3K)
pathway,  transiently  increasing  phospho-Akt  levels.  The
estrogen receptor antagonist tamoxifen did not reverse the
protective effect of 17β-estradiol, but inhibition of the insulin
receptor beta blocked the PI3K mediated protective effects.
This  finding  suggested  that  neuroprotection  with  17β-
estradiol may be independent of its receptors, but dependent
on the PI3K-signaling pathway that is known to promote
neuronal survival. Systemic administration of 17β-estradiol,
in the in vivo arm of the study, demonstrated activation of
insulin receptor beta as well, with a transient increase in PI3K
activity  and  phosphorylation  of  Akt,  protecting  rat
photoreceptor cells [41].
Similarly,  two  recent  studies  addressed  the
neuroprotective  effect  of  17β-estradiol  via  extracellular
signal-regulated kinase (ERK) pathway induction. In the first,
retinas were harvested from female rats, both those that had
received oophorectomy and those that had not, to determine
the effect of optic nerve transection on RGC survival. It was
observed that RGC survival was significantly decreased in
rats  that  had  received  oophorectomy,  but  RGC  loss  was
reduced  with  intravitreal  17β-estradiol  injection  [42].
Protection  was  mediated  via  the  ERK  signal  transduction
pathway. Interestingly, ERK inhibitor U0126 inhibited the
neuroprotective effect observed [42]. In the second study, the
neuroprotective  effect  of  17β-estradiol  against  NMDA-
induced retinal neurotoxicity was examined. In that study,
retinal  pretreatment  with  17β-estradiol  silastic  implants
attenuated RGC death due to intravitreal injection of NMDA
[43].  However,  co-administration  of  U0126  or  estrogen
receptor  antagonist  13-methyl-7[9-(4,4,5,5,5-
pentafluoropentylsulfinyl)nonyl]=7,8,9,11,12,13,14,15,16,1
7-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol  (ICI)
182,780  with  NMDA  completely  abolished  the  protective
effect of 17β-estradiol. Moreover, NMDA treatment alone
significantly increased the levels of phosphorylated ERK (p-
ERK) that increased further with 17β-estradiol pretreatment.
17β-estradiol-induced  increases  in  p-ERK  levels  were
attenuated with administration of U0126 and ICI 182,780
[43].
Our  own  work  has  shown  that  17β-estradiol  and  the
synthetic estrone-derived non-feminizing estrogen analog 2-
(1-adamantyl)-3-hydroxyxyestra-1,3,5(10)-triene-17-one
(ZYC)-3  are  effective  neuroprotectants  against  glutamate-
induced cytotoxicity of RGC-5 rat RGCs [25]. 17β-estradiol
and ZYC-3 afforded complete protection against glutamate-
induced RGC-5 cytotoxicity. As opposed to 17β-estradiol,
ZYC-3 had no appreciable affinity for either estrogen receptor
isoform, but was nearly 20-fold more effective at inhibiting
lipid peroxidation [25]. This study also demonstrated that
ZYC-3  pretreatment  of  glutamate-insulted  RGC-5  cells
elicited  activation  of  a  host  of  anti-apoptotic  signal
transduction pathways.
Signal transduction pathways that are known to affect the
survival of stressed neurons were examined in RGC-5 cells
treated  with  glutamate.  Phosphorylated-Akt  (P-Akt),  also
known as PKB or Rac, plays a critical role in the balance
between survival and apoptosis and is activated by a host of
survival factors [44-46]. The p42 (Erk1) and p44 (Erk2) MAP
kinase  proteins  (activated  by  phosphorylation)  also  play
critical roles in growth and differentiation regulated by a host
of  factors  including  neurotransmitters  and  neurotrophins
[47-50].  Activation  of  phosphorylation  cascades  in  these
pathways has been shown to promote survival of RGCs in a
variety of models of RGC injury and protection [51-54]. The
p90  S6  ribosomal  kinase  family  of  proteins  responds  to
numerous growth factors and is activated by phosphorylation
downstream  of  Erk1  and  Erk2  [55,56].  Additionally,
phosphorylation  of  p53  was  increased  with  ZYC-3
pretreatment. Phosphorylated activation of tumor suppressor
protein p53 plays a major role in response to DNA damage by
arresting the cell cycle and initiating DNA repair or apoptosis
[57-59]. This may indicate cell cycle arrest for DNA repair to
promote cell survival. The pro-apoptotic p38 MAP kinase
pathway serves as a gateway to cytokine and stress responses,
with  activation  via  phosphorylation  leading  to  cell  death
[60-63].  In  models  of  axotomy-induced  apoptosis,
phosphorylation  of  p38  peaked  at  one  day  postaxotomy,
inhibition of p38 phosphorylation attenuated RGC loss, and
selective  inhibition  of  NMDA  receptors  showed  dose-
dependent  attenuation  of  p38  activation,  resulting  in
protection of RGCs [64,65].
These  studies  demonstrate  that  natural  estrogens  and
synthetic analogs are effective neuroprotectants, an outcome
classically attributed to receptor-mediated gene expression.
These  effects  may  also  be  due  to  receptor-independent
activation of signal transduction pathways. While estrogens
may hold promise in treating degenerative retinal disorders
including  AMD,  RP,  and  glaucoma,  most  of  the  studies
discussed  were  conducted  with  natural  estrogens.  As  a
consequence, these studies are subject to criticisms that have
led  to  a  fear  of  HT  within  the  general  population.  An
alternative approach would be to exploit the neuroprotective
virtues of estrogens while attenuating their classic receptor-
mediated  feminizing  effects.  One  of  the  key  receptor-
independent  mechanisms  by  which  estrogens  afford
neuroprotection  occurs  through  scavenging  and  resonance
stabilization of free radicals.
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fundamental  pathogenic  mechanism  of  RGC  death  in
glaucoma [66-68]. Conversely, estrogens have been identified
as  potent  antioxidants  [35,69-73].  Simple  principles  of
organic chemistry suggest that synthetic estrogens have a
future  as  designer  neuroprotective  drugs.  Key  to  their
receptor-independent neuroprotective effects is their ability to
function as direct antioxidants by quenching free radicals and
terminating  their  propagation  [74-76].  This  mechanism
involves donation of a hydrogen atom from the phenolic group
found on the A ring of natural estrogens (Figure 1B), to the
free-radical (Figure 1C), resonance stabilizing the free radical
and terminating chain reactions (Figure 1D). This process
leaves behind a phenoxyl radical that can be regenerated in
vivo [70]. Regeneration of phenolic antioxidants occurs via
three  known  pathways  using  ascorbic  acid,  glutathione-
dependent free-radical reductase, and a recently discovered
NADPH-mediated  reductive  aromatization  (Symbol  X  in
Figure 1) [69,77,78]. This mechanism is key to their function
as direct antioxidants.
Based  on  these  principles,  the  efficacy  of  synthetic
estrogen  derivatives  designed  to  harness  the  antioxidant
capabilities  of  estrogens  without  their  receptor-mediated
feminizing effects will be the choice of future neuroprotective
drugs in this class of compounds (Figure 2). Prodrug quinolic
variants  of  some  compounds  have  also  been  shown  to
attenuate  estrogen  receptor  binding  and  are  believed  to
enhance the ability of the compound to traverse the lipid
bilayer (Figure 1A) [69]. These studies were conducted based
on previously established protocols for treatment of RGC-5
with glutamate to induce an increased oxidative burden to
examine the neuroprotective efficacy of novel compounds
[25]. The drug ZYC-3 was identified as the most effective
neuroprotectant and its mechanisms of action are the subject
of a portion of our work in this field.
Figure 1. Termination, stabilization, and recycling of free-radical by
phenolic estrogen derived drugs. Structure A represents the quinolic
ring that can spontaneously convert to a phenolic ring found in the
structure of estrogens. The phenol (B) can then scavenge free radicals
(C) and resonance-stabilize them (C-D) until reduced (X). Reduction
of phenoxy radicals (C) is an enzyme-mediated process that uses
ascorbic acid, glutathione-dependent free radical reductase, and a
newly discovered NADPH-mediated reductive aromatization. This
illustration was loosely based on work of Prokai et al. [79].
CONCLUSIONS
Estrogens clearly have an impact on the health of the retina.
Figure 2. Examination of the neuroprotective efficacy of estrogens
and analogs. Maximal efficacy, with dose of drug, was examined in
a glutamate-induced cytotoxicity model of in vitro retinal ganglion
cell death using the retinal ganglion cell-5 cell line. This screening
process was used to guide drug selection and design, and to identify
highly efficacious compounds for detailed studies of mechanism of
action.  Abbreviations:  17β-estradiol  (E2)  is
1,3,5(10)estratriene-3,17 beta-diol; E2Q is 3,5(10)estratriene-3,17
beta-diol-quinol;  Estrone  (E1)  is  3-hydroxyestra-1,3,5(10)-
triene-3,17 beta-diol; E1Q is 3-hydroxyestra-1,3,5(10)-triene-3,17
beta-diol-quinol;  17α-estradiol  is  1,3,5(10)estratriene-3,17  alpha-
diol;  17α-estradiol-quinol  is  1,3,5(10)estratriene-3,17  alpha-diol-
quinol; ADAEI is 2-adamantyl-3-hydroxyestra-1,3,5(10)-triene-17-
one; ADAEIQ is 2-adamantyl-3-hydroxyestra-1,3,5(10)-triene-17-
one-quinol;  THN  is  1,3,6,8-tetrahydroxynapthalene;  THNQ  is
1,3,6,8-tetrahydroxynapthalene-quinol;  ZYC1  is  17β
estra-1,3,5(10),  9(11)-tetratriene-3,17-diol;  ZYC-3  is  2-(1-
adamantyl)-3-hydroxyestra-1,3,5(10)-triene-17-one;  ZYC10  is
Enantiomer of ZYC1.
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throughout the retinal thickness, concentrated prominently in
the RGC and nerve fiber layers. At least in part, estrogen
receptors  mediate  the  influence  of  estrogens  on  blood
viscosity  and  ocular  vascularity.  Estrogens  and  female
reproductive factors may also have an impact on IOP and the
development of OAG. The observation that estrogens may
protect against degenerative vision loss in RP, AMD, and
glaucoma  is  suggestive  of  their  retinal  neuroprotective
capabilities, but also paves the way for the development of
non-feminizing  estrogen-like  drugs  that  can  be  used  in
patients regardless of sex or health predispositions. Although
not all novel drugs examined produced complete protection,
even  partial  protection  shows  that  outcome-directed  drug
design  can  be  an  effective  method  of  developing
neuroprotective drugs. These results may then be used to
refine the design of compounds to improve their efficacy. The
capabilities  of  medicinal,  quantitative,  and  computational
chemistry can be used to model free radical scavenging and
resonance  stabilization  to  refine  the  design  of  synthetic
estrogens. Reexamination of such compounds in selective
high throughput in vitro experiments could rapidly produce a
host of efficacious drugs.
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